Treatment-emergent AEs of interest in the safety population
| . | Carfilzomib group (n = 474) . | Bortezomib group (n = 470) . | ||
|---|---|---|---|---|
| . | All grades . | Grade ≥3 . | All grades . | Grade ≥3 . |
| Acute renal failure | 66 (13.9) | 35 (7.4) | 29 (6.2) | 10 (2.1) |
| Cardiac failure | 51 (10.8) | 39 (8.2) | 20 (4.3) | 13 (2.8) |
| PN | 44 (9.3) | 1 (0.2) | 264 (56.2) | 56 (11.9) |
| Ischemic heart disease | 14 (3.0) | 10 (2.1) | 9 (1.9) | 6 (1.3) |
| . | Carfilzomib group (n = 474) . | Bortezomib group (n = 470) . | ||
|---|---|---|---|---|
| . | All grades . | Grade ≥3 . | All grades . | Grade ≥3 . |
| Acute renal failure | 66 (13.9) | 35 (7.4) | 29 (6.2) | 10 (2.1) |
| Cardiac failure | 51 (10.8) | 39 (8.2) | 20 (4.3) | 13 (2.8) |
| PN | 44 (9.3) | 1 (0.2) | 264 (56.2) | 56 (11.9) |
| Ischemic heart disease | 14 (3.0) | 10 (2.1) | 9 (1.9) | 6 (1.3) |
Data are n (%). AEs (Standardized MedDRA Queries narrow search) of clinical interest are shown. The safety population included all patients who received at least 1 dose of a study drug.